Table 6.
Current clinical trials of PDE inhibitors in cardiovascular diseases
| Drug Name | Developer | PDE Selectivity | Indications | Highest CT Phase | |
|---|---|---|---|---|---|
| Ongoing clinical development | ITI-214 | Intra-Cellular Therapies | PDE1 | HF (NCT03387215) | Phase 2 |
| Discontinued or unknown clinical development | Parogrelil | Nissan Chemical Industries | PDE3, PDE5 | Intermittent claudication | Phase 2 |
| Tetomilast | Otsuka Pharmaceutical | PDE4 | HF, reperfusion injury | Phase 2 | |
| SLx-2101 | Surface Logix/Kadmon Pharmaceuticals | PDE5 | Hypertension (NCT00562614) (NCT00562549) | Phase 2 | |
| Zaprinast | Aventis | PDE5, PDE6 | Ischemic heart disease | N/A |
CT, clinical trial; HF, heart failure, N/A, not available; PDE, phosphodiesterase.